Emergent Biosolutions (NYSE: EBS) reported Q2 EPS of $0.13, may not compare to the analyst estimate of $0.32. Revenue for the quarter came in at $110.3 million versus the consensus estimate of $109.25 million.

For earnings history and earnings-related data on Emergent Biosolutions (EBS) click here.